Cetrorelix Acetate (Cetrotide) - Complete Research Paper

1. Summary

Cetrorelix acetate is a synthetic decapeptide GnRH (gonadotropin-releasing hormone) antagonist used to prevent premature ovulation in women undergoing controlled ovarian stimulation for in vitro fertilization (IVF) and other assisted reproductive technologies (ART). As a competitive GnRH receptor antagonist, cetrorelix produces immediate, dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) without the initial "flare" effect seen with GnRH agonists.

FDA Approval: August 11, 2000 (Cetrotide by EMD Serono Inc.) European Approval: 1999 (first "third-generation" GnRH antagonist approved in EU)

Cetrorelix was the first GnRH antagonist available on the European market for controlled ovarian stimulation in IVF and ICSI. It offers the unique advantage of two dosing options: a multiple-dose regimen (0.25 mg daily) or a single-dose regimen (3 mg), allowing clinicians to tailor treatment to individual patient needs. The single-dose option significantly reduces injection burden for patients—median of 1 injection versus 4 or more with daily protocols.

Key Clinical Features:

• Indication: Prevention of premature LH surges during controlled ovarian hyperstimulation for IVF
• Administration: Subcutaneous injection (requires reconstitution)
• Dosing options:
  • 0.25 mg daily (multiple-dose regimen)
  • 3 mg single dose (provides ≥4 days of LH suppression)
• Bioavailability: 85%
• Half-life: Dose-dependent (5 hours for 0.25 mg single dose; ~63 hours for 3 mg single dose)
• Onset: LH suppression within 1-2 hours
• Reversibility: Rapid recovery upon discontinuation
• Generic availability: Yes

Compared to ganirelix (the other major GnRH antagonist for IVF), cetrorelix demonstrates superior LH surge control and lower OHSS incidence, making it preferable for high-risk patients. However, it requires reconstitution before administration and is generally more expensive than ganirelix.

Goal Archetype Integration

Primary Goal Alignment

When Cetrorelix Makes Sense

Optimal Candidate Profile:

• Women undergoing controlled ovarian stimulation for IVF/ICSI
• High OHSS risk patients (PCOS, high AMH >4 ng/mL, previous OHSS)
• Patients preferring fewer injections (3 mg single-dose option)
• Cases requiring precise LH surge control
• Poor responders requiring flexible protocol timing
• Women with history of premature LH surge in previous cycles

Clinical Scenarios Favoring Cetrorelix:

1. PCOS patients - Higher baseline OHSS risk; cetrorelix shows 0.4% OHSS vs. 1.1% ganirelix
2. High responders - Multiple follicle development with elevated estradiol (>3,000 pg/mL)
3. First IVF cycle - Single-dose option reduces patient anxiety about self-injection
4. Patients requiring strict LH suppression - 4.9% LH surge rate vs. 7.6% with ganirelix
5. Freeze-all cycles - Flexible timing integrates well with segmented IVF approaches

When to Choose Something Else

Consider Ganirelix Instead:

• Cost-sensitive patients (ganirelix typically less expensive)
• Patients comfortable with self-injection who prefer pre-filled convenience
• Standard-risk patients without specific OHSS concerns

Consider GnRH Agonist (Long Protocol) Instead:

• Specific donor oocyte protocols requiring extended downregulation
• Some endometriosis-associated infertility protocols
• Patient preference based on prior successful outcomes
• Protocols requiring suppression of endometriosis lesions pre-stimulation

Avoid Cetrorelix When:

• Known hypersensitivity to GnRH analogs
• Confirmed or suspected pregnancy
• Severe renal impairment
• Active lactation

2. Mechanism of Action

Cetrorelix is a synthetic decapeptide analog of native GnRH with amino acid substitutions at positions 1, 2, 3, 6, and 10 that convert it from an agonist to a potent antagonist.

Primary Mechanism: Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary gonadotroph cells. Unlike GnRH agonists, cetrorelix:

• Binds to GnRH receptors WITHOUT activating them
• Produces immediate receptor blockade
• Prevents endogenous GnRH from stimulating LH and FSH release
• Does NOT cause initial gonadotropin release ("flare")

Dose-Dependent Effects: The suppression of LH and FSH is dose-dependent, with a more pronounced effect on LH than on FSH:

| Dose | Onset of LH Suppression | Duration of Suppression | |---

Goal Relevance:

• I want to prevent premature ovulation during my IVF treatment to improve my chances of successful conception.
• I'm looking for a way to manage my fertility treatments with fewer injections and less hassle.
• I need a reliable method to control hormone surges during my ovarian stimulation process.
• I'm trying to optimize the timing of my egg retrieval for better quality oocytes in my IVF cycle.
• I want to reduce the risk of ovarian hyperstimulation syndrome (OHSS) while undergoing fertility treatments.
• I'm seeking a fertility treatment that allows for rapid recovery of natural hormone function after use.
• I need a medication that can help coordinate the development of multiple follicles for IVF.

---|------------------------|------------------------| | 0.25 mg | ~2 hours | ~24 hours | | 3 mg | ~1 hour | ≥4 days |

Structural Modifications: The amino acid substitutions that create antagonist activity:

• Position 1: D-Nal (D-3-(2-naphthyl)alanine)
• Position 2: D-Phe(4-Cl) (4-chloro-D-phenylalanine)
• Position 3: D-Pal (D-3-(3-pyridyl)alanine)
• Position 6: D-Cit (D-citrulline)
• Position 10: D-Ala amide

These modifications provide:

1. High receptor binding affinity
2. Pure antagonist activity (no agonist effect)
3. Extended half-life
4. Reduced histamine-releasing potential (third-generation advantage)

Clinical Relevance in IVF: The natural menstrual cycle includes an LH surge triggered by positive estradiol feedback at mid-cycle. This LH surge causes:

• Ovulation of the dominant follicle
• Resumption of oocyte meiosis
• Luteinization with rising progesterone

In IVF, premature LH surge is problematic because:

• Multiple follicles are stimulated simultaneously
• Premature ovulation would release eggs before scheduled retrieval
• Premature luteinization compromises oocyte quality

Cetrorelix prevents these issues by maintaining LH suppression throughout the stimulation phase until intentional triggering with hCG.

Reversibility: The effects of cetrorelix on LH and FSH are fully reversible after discontinuation, allowing normal pituitary-gonadal function to resume rapidly—essential for subsequent hCG triggering and oocyte maturation.

3. FDA-Approved Indications

Primary Indication: Cetrotide (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation.

Specific Clinical Context: The drug is used in conjunction with exogenous gonadotropins (FSH, hMG) during IVF and ICSI protocols to:

1. Prevent premature ovulation
2. Allow coordinated development of multiple follicles
3. Enable optimal timing of hCG trigger administration
4. Facilitate scheduled oocyte retrieval

Regulatory Status:

Available Strengths (US FDA-Approved):

• 0.25 mg/vial (for multiple-dose regimen)
• 3 mg/vial (for single-dose regimen) — Note: 3 mg formulation has been discontinued in some markets

Manufacturer: EMD Serono, Inc. (Healthcare business of Merck KGaA, Darmstadt, Germany in the US and Canada)

Off-Label Uses (Not FDA-Approved): While not FDA-approved, cetrorelix has been studied for:

• Uterine fibroid treatment (investigational)
• Endometriosis management (investigational)
• Prostate cancer (other GnRH antagonists preferred)
• Polycystic ovary syndrome during ART

Note on Indication Scope: Cetrorelix is specifically approved for fertility treatment in women. Unlike degarelix (a related GnRH antagonist), cetrorelix is NOT approved for:

• Prostate cancer treatment
• Long-term hormone suppression
• Central precocious puberty
• Other hormone-dependent conditions requiring prolonged therapy

4. Dosing and Administration

Dosing Options: Cetrorelix offers two FDA-approved dosing regimens, providing flexibility based on patient preference and clinical judgment.

Multiple-Dose Regimen (0.25 mg daily):

• Dose: 0.25 mg subcutaneous injection once daily
• Initiation: Stimulation day 5 (morning or evening) or day 6 (morning)
• Alternative start: When lead follicle reaches ≥14 mm
• Duration: Continue daily until hCG administration (including day of hCG)
• Mean treatment duration: 5 days (range varies by protocol)

Single-Dose Regimen (3 mg):

• Dose: 3 mg subcutaneous injection (single administration)
• Timing: When estradiol levels indicate appropriate response (typically when lead follicle ≥14 mm)
• Duration of effect: ≥4 days of LH suppression
• Additional dosing: If hCG is not administered within 4 days, administer 0.25 mg once daily until hCG day

Preparation and Administration:

Reconstitution (Required):

1. Clean rubber stopper with alcohol swab
2. Inject 1 mL (0.25 mg) or 3 mL (3 mg) of sterile water into vial
3. Gently swirl until solution is clear (do not shake)
4. Draw reconstituted solution into syringe
5. Inject subcutaneously into lower abdomen (preferably around navel)
6. Rotate injection sites

Administration Tips:

• Inject at approximately the same time each day (for 0.25 mg regimen)
• Preferred injection site: Lower abdominal wall around navel
• Avoid areas with scarring or irritation
• Use provided pre-filled syringe of sterile water for reconstitution

Critical Timing Considerations:

• For 0.25 mg regimen: Do not exceed 24 hours between injections
• Ensure last injection is on day of hCG trigger (or day before for evening injection schedules)
• For 3 mg regimen: If >4 days until hCG, switch to 0.25 mg daily

Product Presentation:

• Cetrotide 0.25 mg kit: Vial with lyophilized powder + pre-filled syringe with diluent + needles
• Cetrotide 3 mg kit: Vial with lyophilized powder + pre-filled syringe with diluent + needles (availability varies by market)

Age-Stratified Dosing

Age is a critical factor in IVF outcomes and influences cetrorelix protocol selection. While the standard dose remains consistent, protocol adjustments optimize outcomes across age brackets.

Women Under 35

Clinical Notes for Under 35:

• Robust ovarian response typically observed
• Standard cetrorelix dosing highly effective
• May be candidates for single-dose protocol to reduce injection burden
• OHSS risk assessment critical due to typically higher follicle counts
• If OHSS risk indicators present, cetrorelix preferred over ganirelix

Women 35-40

Clinical Notes for 35-40:

• Transition period for ovarian reserve
• More variable follicular development
• Multiple-dose (0.25 mg daily) allows protocol flexibility
• Careful monitoring essential for optimal hCG trigger timing
• May require higher gonadotropin doses for stimulation

Women Over 40

Clinical Notes for Over 40:

• Diminished ovarian reserve typical
• Fewer follicles but each oocyte is valuable
• Multiple-dose regimen allows daily adjustment
• LH surge prevention remains essential for quality oocyte retrieval
• Standard cetrorelix dosing effective regardless of follicle count
• Consider natural cycle or mini-IVF protocols where cetrorelix timing adjusted accordingly

Age-Stratified Quick Reference:

5. Pharmacokinetics

Absorption: Cetrorelix is rapidly absorbed following subcutaneous injection:

• Bioavailability: 85% (absolute, following SC administration)
• Time to peak concentration (Tmax): 1-2 hours
• Peak concentration (Cmax):
  • 0.25 mg: ~6 ng/mL
  • 3 mg: ~28 ng/mL

Distribution:

• Volume of distribution (Vd): ~1 L/kg (following single IV dose of 3 mg)
• Protein binding: 86% (to human plasma proteins)
• Tissue distribution: Cetrotide concentrations in follicular fluid are similar to plasma concentrations on the day of oocyte retrieval

Metabolism:

• Primary metabolism via peptidases
• Predominant metabolite: (1-4) peptide
• Cetrorelix is stable against phase I and phase II metabolism
• No significant CYP450 involvement

Elimination:

• Excretion routes:
  • Urine: 2-4% as unchanged drug
  • Bile: 5-10% as cetrorelix and metabolites
  • Total recovery (24 hours): 7-14% of administered dose

Half-Life (Dose and Regimen Dependent):

Pharmacokinetic Characteristics:

• Linear pharmacokinetics across dose range
• Cmax and AUC increase proportionally with dose
• Longer half-life with 3 mg dose explains extended duration of LH suppression (≥4 days)

Special Populations:

• Renal impairment: No formal studies; contraindicated in severe renal impairment
• Hepatic impairment: No formal studies; use with caution
• Elderly: Not applicable (fertility indication)
• Pediatric: Not indicated

Pharmacokinetic/Pharmacodynamic Modeling: Two-compartment pharmacokinetic model with:

• Terminal half-life: 56.9 ± 27.1 hours (modeling study)
• This extended terminal phase explains cumulative effects with repeated dosing

6. Side Effects and Adverse Reactions

Clinical Trial Safety Data: The safety of Cetrotide was evaluated in 949 patients undergoing controlled ovarian stimulation in clinical trials. Patients ranged from 19-40 years of age (mean: 32), with 94% Caucasian. Doses ranged from 0.1 mg to 5 mg as single or multiple doses.

Common Adverse Events:

Local Injection Site Reactions (Most Common):

• Redness/erythema
• Bruising
• Itching/pruritus
• Swelling
• Generally transient, mild intensity, and short duration
• Rarely treatment-limiting

Systemic Adverse Events:

Laboratory Abnormalities:

• ALT elevations: 1-2% of patients
• AST elevations: 1-2% of patients
• GGT elevations: 1-2% of patients
• Alkaline phosphatase elevations: 1-2% of patients
• Range: Up to 3× upper limit of normal
• Clinical significance: Generally asymptomatic and reversible

Serious Adverse Reactions:

Hypersensitivity Reactions:

• Anaphylactoid reactions reported during post-marketing surveillance
• Cases with first dose have been reported
• One severe anaphylactic reaction with cough, rash, and hypotension observed in a patient receiving 10 mg/day for 7 months (non-fertility study)
• Requires immediate medical attention

Ovarian Hyperstimulation Syndrome (OHSS):

• Can be serious; caused by ovarian stimulation protocol
• Symptoms: Enlarged swollen ovaries, abdominal pain/distension, fluid leakage
• Cetrorelix protocols may reduce OHSS risk compared to GnRH agonist protocols
• 2025 comparative study: Cetrorelix associated with 0.4% OHSS vs. 1.1% with ganirelix

Drug-Related Allergic Reactions: No drug-related allergic reactions were reported from Phase 2 and Phase 3 clinical studies (N=949).

Pregnancy-Related Events (in Resulting Pregnancies): In clinical trials, 184 pregnancies occurred in 732 patients. Reported outcomes related to IVF population, not necessarily drug-related:

• Spontaneous abortion (consistent with IVF population rates)
• Ectopic pregnancy
• Fetal death

Congenital Anomalies Reported (in Resulting Offspring): Major anomalies in 4 pregnancies (therapeutic abortions):

• Diaphragmatic hernia
• Trisomy 21
• Klinefelter syndrome
• Polymalformation
• Trisomy 18

Note: ICSI was used in 3 of 4 cases. Causal relationship unclear; multiple confounding factors.

Minor anomalies reported:

• Supernumerary nipple
• Bilateral strabismus
• Imperforate hymen
• Congenital nevi
• Hemangiomata
• QT syndrome

7. Drug Interactions

Clinically Significant Interactions: Cetrorelix has minimal documented drug interactions due to its specific mechanism of action and metabolic profile.

Pharmacokinetic Interactions:

• No significant CYP450 enzyme inhibition or induction
• Peptidase metabolism (not hepatic microsomal enzymes)
• No expected drug-drug interactions via metabolic pathways
• No significant protein binding displacement interactions expected

Pharmacodynamic Interactions:

Intended Combinations: Cetrorelix is specifically designed for use WITH:

• Follicle-stimulating hormone (FSH) preparations (Gonal-F, Follistim)
• Human menopausal gonadotropin (hMG) (Menopur)
• Human chorionic gonadotropin (hCG) for ovulation trigger
• Progesterone for luteal support

Contraindicated Combinations:

• GnRH agonists (leuprolide, goserelin, etc.) — opposing mechanisms
• Other GnRH antagonists (ganirelix) — no benefit to combining

Foods and Supplements:

• No known food interactions
• No documented supplement interactions
• No dietary restrictions required

Laboratory Test Interactions:

• Expected suppression of LH and FSH levels (pharmacodynamic effect)
• Hormone assays should be interpreted in context of cetrorelix treatment
• Liver enzymes may be transiently elevated (see adverse reactions)

8. Contraindications

Absolute Contraindications:

1. Known hypersensitivity to cetrorelix acetate, extrinsic peptide hormones, or any component of the product
2. Known hypersensitivity to GnRH or any GnRH analog (structural class hypersensitivity)
3. Known or suspected pregnancy — use can cause fetal harm
4. Lactation (breastfeeding women)
5. Severe renal impairment — no pharmacokinetic data; potential accumulation

Pregnancy Warning (Critical):

• Using cetrorelix if already pregnant can cause birth defects, miscarriage, or stillbirth
• Pregnancy MUST be excluded before starting treatment
• Barrier contraception should be used before IVF cycle initiation

Mechanism of Harm in Pregnancy: GnRH antagonists suppress gonadotropin release critical for:

• Corpus luteum maintenance in early pregnancy
• Progesterone production
• Embryo implantation and support

Latex Allergy Consideration: The packaging may contain natural rubber latex; patients with latex sensitivity should be informed.

Relative Contraindications/Precautions:

1. Moderate renal impairment: Use with caution; limited data
2. Hepatic impairment: Use with caution; limited data
3. History of severe allergic reactions: Increased hypersensitivity risk
4. Active or prior allergic conditions: Monitor closely

Not Contraindicated But Requiring Caution:

• Advanced maternal age (≥35 years)
• Poor ovarian reserve
• History of OHSS
• PCOS
• Multiple prior IVF cycles

9. Special Populations

Pregnancy (Category X):

• Absolutely contraindicated
• Pregnancy test required before treatment initiation
• If pregnancy occurs during treatment, discontinue immediately
• Animal studies show dose-dependent fetal resorption
• No adequate human studies in pregnant women

Lactation:

• Contraindicated during breastfeeding
• Unknown if excreted in human milk
• Potential for serious adverse effects in nursing infants
• Decision required: Discontinue nursing or avoid treatment

Pediatric Use:

• Safety and efficacy not established in children
• Not indicated for pediatric patients
• GnRH antagonists used for central precocious puberty are different compounds

Geriatric Use:

• Not applicable (fertility indication for reproductive-age women)
• No clinical studies in elderly patients

Renal Impairment:

• Mild: No formal dose adjustment; use with caution
• Moderate: Use with caution; limited pharmacokinetic data
• Severe: CONTRAINDICATED — no data available, risk of accumulation

Hepatic Impairment:

• Mild-moderate: Use with caution; limited data
• Severe: Use with caution; no formal studies
• Monitor liver enzymes given reported transient elevations

Women with PCOS:

• Higher baseline risk for OHSS
• GnRH antagonist protocols (including cetrorelix) may reduce OHSS risk
• Lower gonadotropin doses typically recommended
• Close monitoring essential

Poor Ovarian Responders:

• May have reduced follicular development regardless of protocol
• Standard cetrorelix dosing appropriate
• Earlier initiation may be considered
• Careful monitoring of ovarian response

High Responders:

• Cetrorelix may be advantageous due to lower OHSS risk
• Consider GnRH agonist trigger option with antagonist protocol
• Careful estradiol monitoring

Obesity:

• No formal dose adjustment studies
• Standard dosing appears effective
• Consider injection site selection for subcutaneous absorption

10. Monitoring Parameters

Pre-Treatment Assessment:

During Treatment Monitoring:

Ultrasound Surveillance:

• Transvaginal ultrasound every 1-3 days during stimulation
• Assess number and size of developing follicles
• Monitor for OHSS signs (ovarian enlargement, ascites)
• Determine optimal timing for hCG trigger

Hormonal Monitoring:

Criteria for LH Surge Concern:

• LH ≥10 IU/L may indicate inadequate suppression
• Cetrorelix demonstrates lower incidence of LH ≥10 IU/L (4.9%) compared to ganirelix (7.6%)

OHSS Risk Assessment: Monitor for high-risk indicators:

• Estradiol >3,000-4,000 pg/mL

• 15-20 developing follicles

• Rapid estradiol rise (>75% in 24-48 hours)
• History of OHSS
• PCOS diagnosis

Intervention Strategies if High OHSS Risk:

• "Coasting" (withholding gonadotropins)
• GnRH agonist trigger instead of hCG
• Freeze-all embryos
• Cycle cancellation in severe cases

Injection Site Monitoring:

• Assess for local reactions (erythema, swelling, pruritus)
• Rotate injection sites
• Severe or persistent reactions warrant evaluation

Liver Function Monitoring:

• Consider periodic LFT monitoring given 1-2% incidence of enzyme elevations
• Monitor if baseline abnormalities exist

Post-Trigger Timing:

• hCG trigger when lead follicles ≥18 mm
• Oocyte retrieval: 34-36 hours after trigger
• Initiate luteal phase support as per clinic protocol

11. Cost and Availability

Pricing (United States, 2024-2025):

Brand-Name Cetrotide:

Generic Cetrorelix:

Note: Significant savings available with discount programs (GoodRx, SingleCare)

Cost Comparison with Ganirelix:

Generic Availability:

• Cetrorelix acetate is available as a generic medication
• Brand name: Cetrotide (EMD Serono)
• Generic manufacturers available in some markets
• Note: Some sources indicate limited generic availability

Insurance Coverage:

• Medicare: Does NOT cover Cetrotide or cetrorelix (fertility exclusion)
• Private insurance: Variable coverage based on fertility benefits
• Prior authorization: Often required when coverage exists
• State mandates: Some states (IL, MA, CT, NJ, NY, RI, MD) require infertility coverage

Cost Considerations:

• Specialty medication requiring specialty pharmacy access
• Often purchased through fertility clinic dispensaries
• Discount fertility medication vendors may offer savings
• HSA/FSA eligible expense
• Out-of-pocket costs substantial without coverage

International Availability:

• United States: Cetrotide (EMD Serono), generic cetrorelix
• European Union: Cetrotide (Merck KGaA affiliates)
• Canada: Cetrotide
• Global: Available in 45+ countries
• Australia: Cetrotide

Product Presentation: Cetrotide 0.25 mg kit contains:

• 1 vial lyophilized cetrorelix acetate
• 1 pre-filled syringe with sterile water for reconstitution
• 20-gauge needle for reconstitution
• 27-gauge needle for injection

12. Clinical Evidence Summary

Pivotal Clinical Trials:

Phase 2 and Phase 3 Registration Studies: Combined data from clinical trials demonstrated:

• Total patients studied: 949 women undergoing controlled ovarian stimulation
• Age range: 19-40 years (mean 32 years)
• Doses tested: 0.1 mg to 5 mg (single and multiple dose)

Efficacy Outcomes: From 732 patients in Phase 2/3 trials:

• 184 clinical pregnancies achieved (25.1% per patient)
• Additional 21 pregnancies from frozen embryo transfer
• Pregnancy rates comparable to GnRH agonist protocols

LH Surge Prevention:

Comparative Studies:

Cetrorelix vs. Ganirelix (2025 Retrospective Cohort): Large-scale comparison (2,365 cetrorelix vs. 7,059 ganirelix patients after PSM):

Key Finding: Cetrorelix demonstrates superior LH surge control and lower OHSS incidence compared to ganirelix.

Cetrorelix vs. GnRH Agonist Long Protocol: Multiple studies demonstrate:

• Equivalent pregnancy rates
• Shorter stimulation duration with antagonist
• Fewer injections required
• Lower OHSS incidence with antagonist
• Reduced gonadotropin consumption

Dose-Finding Studies: 0.25 mg daily dose selected based on:

• Effective LH surge prevention
• Minimal side effects
• Convenient once-daily administration
• Balance of efficacy and tolerability

Single vs. Multiple Dose Protocols: The 3 mg single-dose option provides:

• ≥4 days of LH suppression
• Significantly fewer injections (median 1 vs. 4+)
• Comparable efficacy to daily dosing
• Patient convenience advantage

Safety Database:

• 949 patients in clinical trials
• Well-established safety profile
• No drug-related allergic reactions in clinical studies
• Post-marketing surveillance confirms safety

13. Comparison with Alternatives

GnRH Antagonist Comparison: Cetrorelix vs. Ganirelix

Clinical Recommendations:

• For high OHSS risk: Cetrorelix preferred (lower incidence)
• For strict LH control: Cetrorelix preferred (superior suppression)
• For cost-conscious patients: Ganirelix preferred
• For patient convenience (fewer injections): Cetrorelix 3 mg single-dose
• For self-administration ease: Ganirelix (no reconstitution)

GnRH Antagonist vs. GnRH Agonist Protocols:

When to Choose Cetrorelix:

1. High-risk OHSS patients (PCOS, high AMH, previous OHSS)
2. Patients preferring fewer injections (3 mg option)
3. Need for precise LH control
4. Desire for shorter protocol duration
5. Cost considerations (lower overall cycle cost)
6. Poor responders (flexibility in timing)

When GnRH Agonist May Be Preferred:

1. Long history of successful outcomes with agonist
2. Specific donor protocols
3. Some endometriosis protocols
4. Patient/physician preference

14. Storage and Handling

Storage Conditions:

Unopened Product:

• Temperature: Store at 25°C (77°F); excursions permitted 15-30°C (59-86°F)
• Special conditions: Store in original package to protect from light
• Refrigeration: Not required (room temperature storage acceptable)
• Freezing: Do NOT freeze

After Reconstitution:

• Use immediately after reconstitution
• Do not store reconstituted solution
• Discard any unused portion

Reconstitution Procedure:

1. Wash hands thoroughly
2. Flip off plastic cover of vial
3. Clean rubber stopper with alcohol swab; allow to dry
4. Remove pre-filled syringe from package
5. Attach 20-gauge needle to syringe
6. Inject diluent into vial slowly, directing stream at glass wall
7. Gently swirl vial until solution is clear (do NOT shake)
8. Invert vial and withdraw all solution into syringe
9. Replace 20-gauge needle with 27-gauge needle for injection
10. Check for air bubbles; expel if present

Visual Inspection:

• Solution should be clear and colorless
• Do NOT use if:
  • Solution is cloudy
  • Contains particles
  • Solution is discolored
  • Vial/syringe is damaged

Handling Precautions:

• Single-use vials only
• Do not reuse needles or syringes
• Use aseptic technique during reconstitution
• Latex allergy consideration: Check packaging components

Disposal:

• Dispose of used needles and syringes in sharps container
• Do not dispose in regular household trash
• Follow local regulations for pharmaceutical waste

Stability:

• Shelf life: Refer to expiration date on package
• Do not use after expiration date
• Store in original carton until ready to use

Travel Considerations:

• Room temperature transport acceptable
• Protect from extreme heat/cold
• Keep reconstitution supplies together
• Consider travel letter from physician for international travel

15. References

1. FDA Drug Approval Package: Cetrotide (Cetrorelix Acetate) NDA #21-197. Approved August 11, 2000. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21-197_Cetrotide.cfm

2. Cetrotide® 0.25 mg (cetrorelix acetate for injection) Prescribing Information. EMD Serono, Inc. 2023. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021197s017s022lbl.pdf

3. DrugBank. Cetrorelix: Uses, Interactions, Mechanism of Action. Available at: https://go.drugbank.com/drugs/DB00050

4. Frydman R, Cornel C, de Ziegler D, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod. 1998;13(9):2392-2398.

5. Olivennes F, Fanchin R, Bouchard P, et al. Cetrorelix in reproductive medicine. Drugs. 2002;62(12):1721-1731.

6. Comparison of pregnancy outcomes and safety between cetrorelix and ganirelix in IVF/ICSI antagonist protocols: a retrospective cohort study. Front Reprod Health. 2025. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12034626/

7. Cetrorelix in reproductive medicine. PMC 2023. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10201282/

8. Mayo Clinic. Cetrorelix (subcutaneous route) - Side effects & dosage. Available at: https://www.mayoclinic.org/drugs-supplements/cetrorelix-subcutaneous-route/description/drg-20062654

9. GoodRx. Cetrotide 2025 Prices, Coupons & Savings Tips. Available at: https://www.goodrx.com/cetrotide

10. Medscape. Cetrotide (cetrorelix) dosing, indications, interactions, adverse effects. Available at: https://reference.medscape.com/drug/cetrotide-cetrorelix-342750

11. Drugs.com. Cetrorelix Monograph for Professionals. Available at: https://www.drugs.com/monograph/cetrorelix.html

12. EMD Serono Fertility. Cetrotide (cetrorelix acetate for injection). Available at: https://www.emdseronofertility.com/en/home/our-medications/cetrotide.html

Document compiled from FDA prescribing information, peer-reviewed literature, and clinical practice guidelines. Last updated: December 2024.

Status: PAPER 67 OF 76 COMPLETE

Next Paper: #68 - Somatropin (Genotropin)